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Background: Experimental autoimmune encephalomyelitis (EAE) is an autoimmune, inflammatory disease of the
central nervous system that is widely used as a model of multiple sclerosis (MS). Mitochondrial dysfunction appears
to play a role in the development of neuropathology in MS and may also play a role in disease pathology in EAE.
Here, surface enhanced laser desorption ionization mass spectrometry (SELDI-MS) has been employed to obtain
protein expression profiles from mitochondrially enriched fractions derived from EAE and control mouse brain. To
gain insight into experimental variation, the reproducibility of sub-cellular fractionation, anion exchange
fractionation as well as spot-to-spot and chip-to-chip variation using pooled samples from brain tissue was
examined.
Results: Variability of SELDI mass spectral peak intensities indicates a coefficient of variation (CV) of 15.6% and
17.6% between spots on a given chip and between different chips, respectively. Thinly slicing tissue prior to
homogenization with a rotor homogenizer showed better reproducibility (CV = 17.0%) than homogenization of
blocks of brain tissue with a TeflonW pestle (CV = 27.0%). Fractionation of proteins with anion exchange beads prior
to SELDI-MS analysis gave overall CV values from 16.1% to 18.6%. SELDI mass spectra of mitochondrial fractions
obtained from brain tissue from EAE mice and controls displayed 39 differentially expressed proteins (p≤ 0.05) out
of a total of 241 protein peaks observed in anion exchange fractions. Hierarchical clustering analysis showed that
protein fractions from EAE animals with severe disability clearly segregated from controls. Several components of
electron transport chain complexes (cytochrome c oxidase subunit 6b1, subunit 6C, and subunit 4; NADH
dehydrogenase flavoprotein 3, alpha subcomplex subunit 2, Fe-S protein 4, and Fe-S protein 6; and ATP synthase
subunit e) were identified as possible differentially expressed proteins. Myelin Basic Protein isoform 8 (MBP8)
(14.2 kDa) levels were lower in EAE samples with advanced disease relative to controls, while an MBP fragment
(12. 4kDa), likely due to calpain digestion, was increased in EAE relative to controls. The appearance of MBP in
mitochondrially enriched fractions is due to tissue freezing and storage, as MBP was not found associated with
mitochondria obtained from fresh tissue.
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Conclusions: SELDI mass spectrometry can be employed to explore the proteome of a complex tissue (brain) and
obtain protein profiles of differentially expressed proteins from protein fractions. Appropriate homogenization
protocols and protein fractionation using anion exchange beads can be employed to reduce sample complexity
without introducing significant additional variation into the SELDI mass spectra beyond that inherent in the
SELDI- MS method itself. SELDI-MS coupled with principal component analysis and hierarchical cluster analysis
provides protein patterns that can clearly distinguish the disease state from controls. However, identification of
individual differentially expressed proteins requires a separate purification of the proteins of interest by
polyacrylamide electrophoresis prior to trypsin digestion and peptide mass fingerprint analysis, and unambiguous
identification of differentially expressed proteins can be difficult if protein bands consist of several proteins with
similar molecular weights.Background
Multiple sclerosis (MS) is an inflammatory neurodegen-
erative disease of the central nervous system (CNS)
characterized by demyelination, oligodendrocyte loss,
axonal damage and neurodegeneration which results in
progressive physical and cognitive disability [1]. Experi-
mental autoimmune encephalomyelitis (EAE) is an auto-
immune, inflammatory disease of the central nervous
system that mimics many of the clinical and histological
features of MS, including the presence of cellular infil-
trates as well as demyelination and axonal degeneration
in the CNS [2,3]. As a result, EAE has been widely
employed as a model for studying the pathogenesis of
MS and for the development of therapeutic approaches
to treat the disease [4-8]. There is much interest in the
role of oxidative stress and mitochondrial dysfunction in
human disease including cardiovascular disease and neu-
rodegenerative diseases [9-12]. A number of studies im-
plicate mitochondrial dysfunction in the development of
neuropathology in MS. Decreases in the neuronal mito-
chondrial metabolite N-acetyl aspartate (NAA) in MS
brain have been observed by nuclear magnetic resonance
spectroscopy and a decrease in NAA appears to precede
neuronal atrophy, suggesting that mitochondrial dys-
function may precede neurodegeneration [13,14]. Alter-
ations to mitochondrial enzyme activity and damage to
mitochondrial DNA have been observed in MS white
matter lesions [16-20]. In addition, defects in mitochon-
drial electron transport gene expression and function in
normal appearing gray matter (NAGM) in postmortem
MS cortex have been reported [21,22]. Mitochondrial
dysfunction may also play a role in disease pathology in
EAE. Increased nitration of components of the electron
transport chain leads to decreased mitochondrial activity
in EAE [15].
Proteomic profiling has been successfully employed in
the discovery and identification of biomarkers in neuro-
degenerative diseases [23,24] and in the analysis of mito-
chondrial proteomes in disease [12]. A number of
studies utilizing proteomic approaches to investigate thedifferentially expressed proteins in MS and EAE have
been reported [25-33]. Proteomic profiling is a rapidly
developing technology that may provide clues to the
mechanisms underlying the onset and progression of
these diseases. A variety of approaches are available for
the analysis of proteomes, including 2D polyacrylamide
gel electrophoresis (2D-PAGE) and Differential Gel
Electrophoresis (DIGE) [34-36], liquid chromatography
coupled to high resolution mass spectrometry (LC-MS),
where label-free [37] as well as ICAT [38] and iTRAQ
[39] labeling strategies are available for quantitative work
and differential analysis [40], and Surface Enhanced
Laser Desorption/Ionization Mass Spectrometry (SELDI-
MS) [41-44].
SELDI-MS was originally developed for rapid, high
throughput biomarker discovery in biological fluids
(plasma, serum, urine, cerebrospinal fluid) but has been
employed to examine the proteomes of cell lysates and
tissues [43,45]. The approach combines time-of-flight
mass spectrometry with protein capture using a variety
of chromatographic protein chip surfaces (anion and
cation exchange, normal phase, reverse phase, and
immobilized metal ion) as well as chemistries for cova-
lent attachment of proteins for affinity capture. It is
most sensitive for monitoring low molecular weight
(< 20kDa) proteins and peptides. Complex protein sam-
ples may also be fractionated (i.e. fractionation on anion
exchange beads) prior to spotting protein chips in order
to reduce the complexity of SELDI mass spectra. SELDI-
MS Expression Difference Mapping allows rapid analysis
of multiple samples over multiple conditions to identify
differentially expressed proteins. Principal component
analysis (PCA) and hierarchical clustering can also be
employed to identify the mass spectral peaks that distin-
guish disease from controls [46-51]. Reproducibility
in various proteome profiling technologies, including
SELDI-TOF mass spectrometry, has been a major chal-
lenge. Sources of variability intrinsic to the SELDI-MS
technique include variation in the ionization and desorp-
tion processes and in time-of-flight measurement and
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spectral preprocessing steps such as baseline correction,
normalization, and mass spectra alignment. Attempts to
reduce proteome complexity and enhance protein identi-
fication by the use of sample fractionation steps, includ-
ing sub-cellular and anion exchange fractionation, can
also introduce variability from sample to sample.
In this study, we used SELDI-TOF-MS to obtain pro-
tein profiles from mitochondrially-enriched fractions
derived from EAE and control mouse brain. To gain
insight into sources of experimental variability, we ex-
amined the reproducibility of sub-cellular fractionation,
anion exchange fractionation as well as spot-to-spot and
chip-to-chip variation using pooled samples from brain
tissue.
Results
Spot-to-spot and chip-to-chip variability
In order to obtain a measure of the reproducibility of
the SELDI mass spectral analysis, equal volumes (1.0 μL)
of anion exchange fraction Q1 from the cytosolic frac-
tion of pooled mouse brain tissue was spotted onto four
NP20 protein chips (eight spots per chip) allowing an

















































Figure 1 Reproducibility of SELDI-TOF-MS spectra. Examples of SELDI m
the cytosolic fraction of pooled mouse brain tissue spotted in eight replicawell as chip-to-chip variation. The SELDI-MS spectra of
each spot (A-H) obtained for one NP20 protein chip is
shown in Figure 1. A total of eighteen peaks with signal/
noise (S/N) > 5 were found to be common to all spectra
measured on this chip which represented proteins with
m/z ratios in the range from 7,500 to 42,772 Da. All
spectra have very similar peak patterns as expected for
replicates from the same pooled sample. Sources of vari-
ability include variation in manually spotting proteins on
the chip, the reproducibility of the manufactured spot
surfaces, and the intrinsic variation in the ionization and
desorption process and in ion time-of-flight and detec-
tion. The coefficient of variation for each peak is listed
in Table 1. The overall coefficient of variation for the
peak intensity for this protein chip was 17.3%. No sig-
nificant differences in the variability of peak intensities
were observed as a function of mass/charge ratio. Ana-
lysis of the other three NP20 chips gave similar results
with overall coefficients of variation for the peak inten-
sities of 13.6%, 16.1%, and 15.3%, suggesting an average
coefficient of variation for spot-to-spot variability of
15.6%. A similar analysis of the chip-to-chip variability
of peak intensities suggests a slightly larger overall coef-











ass spectra obtained for samples of anion exchange fraction Q1 from
tes (A-H) onto an NP20 Protein Chip.
Table 1 Spot-to-spot variability of SELDI-TOF mass
spectra
Peak Intensity Peak M/Z
Peak Mean STD CV% Mean STD CV%
1 16.0 2.4 15.3 7496.3 2.6 0.03
2 18.5 3.2 17.1 8558.0 2.3 0.03
3 28.5 3.9 14.0 9900.3 3.3 0.03
4 21.2 5.8 27.2 10254.0 1.9 0.02
5 20.8 2.7 13.2 10860.5 2.6 0.02
6 16.8 4.1 24.7 11819.5 3.6 0.03
7 10.9 3.2 29.5 12120.4 3.9 0.03
8 9.1 1.8 20.2 12360.3 3.8 0.03
9 4.1 0.6 13.8 20791.1 16.9 0.08
10 4.8 0.6 12.5 22253.6 16.3 0.07
11 7.4 1.3 17.4 24904.4 18.0 0.07
12 6.0 1.5 24.8 28150.4 18.0 0.07
13 9.1 1.0 11.5 29033.2 25.3 0.09
14 12.0 2.1 17.7 30038.2 11.6 0.04
15 11.6 2.1 17.9 30893.0 9.2 0.03
16 6.3 0.6 10.1 33025.8 24.7 0.07
17 6.8 0.7 10.0 39397.1 21.8 0.06
18 6.0 0.8 13.9 42781.4 20.9 0.05
The mean, standard deviation, and coefficient of variation (CV%) for eighteen
protein peaks from an ion exchange fraction (Q1) of the cytosolic fraction of
pooled mouse brain tissue. The overall CV% for peak intensity and m/z ratio
on this chip were 17.3% and 0.05%, respectively.
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gle machines [52-54].
Reproducibility of homogenization and subcellular
fractionation protocols
Depletion of high abundance proteins and fractionation
of samples to reduce proteome complexity prior to
SELDI-TOF MS analysis can increase the number of
detected peaks but can introduce additional variability
into the analysis beyond that associated with the SELDI
MS method itself [55,56]. In order to focus on possible
differences in the mitochondrial proteome, to reduce the
proteome complexity of brain tissue, and increase the
number of detected peaks, particularly for low abun-
dance proteins, we employed sub-cellular fractionation
as well as anion exchange fractionation. Our recent work
on the proteomics of Multiple Sclerosis has focused on
changes occurring in normal appearing grey matter
(NAGM) rather than in whole brain or white matter tissue
that might include lesions. This type of analysis requires a
tissue preparation protocol in which brain tissue is cut
into thin slices and the slices flanking the tissue to be
homogenized are examined under a microscope to con-
firm the absence of lesions prior to homogenization.We have therefore compared the reproducibility of
two homogenization methods: method M1, in which
tissue was thinly sliced (60 μm, ~ 250 mg) prior to
homogenization with a rotor homogenizer (Brinkmann
blender), and method M2, in which blocks (~250 mg) of
brain tissue were cut and homogenized with a mechan-
ical homogenizer (TeflonW pestle). To conduct the
analysis, pooled mouse brain tissue (n=6) was fraction-
ated into enriched nuclear, cytosolic, and mitochondrial
fractions. Three trials were conducted for each homoge-
nization method.
The cytosolic fraction was spotted as four replicates
onto NP20 chips. Examples of SELDI mass spectra for
the cytosolic Q1 fraction from each trial obtained with
the two homogenization methods are shown in Figure 2.
Fourteen peaks with S/N >5 were found to be common
to all mass spectra analyzed across the two homoge-
nization protocols and represent proteins with mass/
charge ratios from 7,492 Da to 42,764 Da. The coeffi-
cients of variation for each peak are listed in Table 2 and
varied from 8.2% to as much as 60.7%. Overall,
homogenization method M1, in which tissue was thinly
sliced prior to homogenization with a rotor homoge-
nizer, shows better reproducibility than method M2, in
which blocks of brain tissue were cut and homogenized
with a mechanical homogenizer.
The overall coefficient of variation for method M1 was
17.0% compared with 27.0% for method M2.
The two methods gave a similar pattern of protein in-
tensities, and significant differences in mean peak inten-
sities with the two homogenization methods were
observed only for one protein peak (m/z = 11,814 Da).
Nevertheless, it is clear that method M2 introduces sig-
nificant additional variability beyond that contributed by
the SELDI-MS method itself, while homogenization
method M1 together with the subcellular fractionation
method employed here yield highly reproducible protein
samples for proteomic analysis.
Reproducibility of anion exchange fractionation
The use of anion exchange beads to fractionate samples
prior to SELDI-MS analysis greatly improves the
resulting mass spectra, but the procedure must be highly
reproducible in order to avoid differences in protein re-
tention on the beads or release from the beads, which
would alter protein profiles of the fractions from sample
to sample. To this end, buffer concentrations and pH
must be carefully monitored and, ideally, anion exchange
fractionation performed on all samples on the same day,
as was the case with this analysis. Anion exchange of
cytosolic fractions with BioSepra Q Ceramic HyperD
anion exchange beads yielded six fractions (Q1– Q6).
Three trials were performed and three fractions (Q1,










































































Figure 2 Reproducibility of subcellular fractionation. Examples of SELDI mass spectra obtained for three replicates of the anion exchange
fraction Q1 from the cytosolic fraction of pooled mouse cytosolic homogenized using method M1 (top) and method M2 (bottom).
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found that were common to all SELDI mass spectra of
fraction Q1. The overall coefficient of variation for the
peak intensities was 16.1%. Analyses of fraction Q2,
with 11 peaks common to all spectra, and Q4, with 8
peaks common to all spectra, gave overall coefficients
of variation of 18.6% and 17.3% for peak intensity,
respectively.
These results suggest that anion exchange pre-
fractionation can be performed reproducibly and does
not introduce significant additional variation to the
SELDI mass spectra beyond that inherent in the SELDI-
MS method itself, which is comparable to the variability
reported by other SELDI-MS users [52,54].
EAE protein expression profiles
The clinical appearance of EAE is of an ascending myeli-
tis, the severity of which is scored on a scale from
0 (normal animal) to 5 (moribund state). SELDI mass
spectra were determined for mitochondrial fractions
obtained from brain tissue from one mouse (labeled E1)
at EAE disease stage 1 (animals display tail paralysis with
mild meningeal inflammation), and four mice (labeled
E2 – E5) at EAE disease stage 3 (animals displaycomplete paralysis of one or both hind limbs with severe
meningitis, and parenchyma infiltration with multiple
perivascular infiltration), as well as from brain tissue
from three controls (labeled C1 – C3). The mitochon-
drial subcellular fractions were further fractionated on
anion exchange beads to give six fractions (Q1- Q6) for
SELDI-MS analysis. A total of 241 protein peaks (clus-
ters) were identified in these six fractions which met our
selection criteria. A total of 39 protein peaks were found
to be differentially expressed (p≤ 0.05) (see Table 3).
Eleven proteins were found at greater levels in EAE
brains relative to controls and 28 proteins were found at
lower levels in EAE brains relative to controls. As shown
in Table 3, the differentially expressed proteins are seen
in all six anion exchange fractions (Q1-Q6) and include
proteins with mass/charge ratios from 3,006 to 49,085
Da. This represents a large fraction (16%) of the ob-
served peaks, and it is possible that some proteins have
been counted twice (i.e. they are observed under both
the LMW and HMW acquisition conditions employed
here), for example, the protein peaks at mass/charge ra-
tios of 13,365 (HMW) and 13,331 (LMW) in fraction
Q2; 12,448 (HMW) and 12,493 (LMW) in fraction Q3;
16,910 (HMW) and 16,878 (LMW) in fraction Q5; and


















Overall CV% 17 27
The coefficient of variation (CV%) for fourteen protein peaks from an ion
exchange fraction (Q1) of the cytosolic fraction of pooled mouse brain tissue
obtained for two homogenization protocols in which tissue was either thinly
sliced prior to homogenization with a Brinkmann rotor homogenizer (method
M1) or tissue was cut into ~250 mg blocks and homogenized with a Teflon
pestle (method M2). The overall CV% for the peak intensities was 17.0% for
method M1 and 27% for method M2.
Azzam et al. Proteome Science 2013, 11:19 Page 6 of 17
http://www.proteomesci.com/content/11/1/1913,854 (HMW) and 13,809 (LMW) in fraction Q6. In
addition, some peaks with different m/z ratios may rep-
resent proteolytic fragments of the same protein.
Protein expression profiles were further analyzed with
hierarchical clustering techniques [49] and principal
component analysis (PCA) [46,47,57]. Hierarchical clus-
tering of differentially expressed proteins employed a
modified Pearson product-moment correlation coeffi-
cient as a distance measure and used the average linkage
method to compute dendrograms in which the nodes
join “objects” (protein fractions) with the most similar
protein expression profiles. The relative length of the
branches indicates the similarity of the expression
profiles.
The result of a hierarchical clustering analysis of frac-
tion Q3 obtained with a HMW data acquisition protocol
is given in Figure 3C and shows that the protein frac-
tions are segregated into two distinct groups: (EAE stage
3) and (controls + EAE stage 1). This clustering of the
EAE disease stage 1 sample with controls was also ob-
served with fraction Q2 (Figure 4B). However, the segre-
gation of EAE disease stage 1 with controls may not be
significant as only one sample at this disease stage was
examined.
Principal component analysis allows us to explore pat-
terns and identify the most important sources ofvariation in large datasets. Principal component analysis
computes a set of orthogonal directions called principal
components. The first principal component is the eigen-
vector of the covariance matrix which has the largest
eigenvalue and accounts for the greatest variation in the
data. The second principal component (i.e. with the next
largest eigenvalue) is the eigenvector, orthogonal to the
first principal component, which accounts for the next
most variance, and so on. The contribution of each prin-
cipal component to a particular protein expression pro-
file is given by the principal component score. The first
several principal components often account for much of
the variability in the data and indicate which features
most contribute to this variability, while the principal
component scores relate that variability to each sample.
As a result, the essential features of the data can often
be captured in a model of much smaller dimensionality
than the original dataset. In the case of the Q3 HMW
dataset, the first three principal components account for
~84% of the variability in the data. A scatter plot
(Figure 3B) of the scores for principal components 1 and
2 clearly shows the segregation of the dataset into EAE
and control samples. Analysis of other fractions shows a
similar behavior. For example, the scatter plot of scores
for principal components 1 and 2 obtained from a Prin-
cipal Component Analysis of fraction Q6 with a LMW
acquisition protocol (Figure 5) also shows a clear segre-
gation of EAE and control samples. Hierarchical cluster-
ing analysis can help identify interesting correlations
among peaks. For example, the lowest node in the den-
drogram for fraction Q6 LMW consists of five highly
correlated peaks at 3006, 3040, 3266, 4020, and 4272 Da
suggesting a strong relationship between the peaks.
Three of them are differentially expressed with p values
of 0.03. Without further analysis, the basis of this correl-
ation cannot be determined, but strongly correlated
peaks in this mass range could reflect proteolytic frag-
ments of the same protein, the expression of a set of
related proteins in response to a stimulus, or post-
translationally modified species.
Principal component analysis of fraction Q2 with a
LMW acquisition protocol (Figure 4) shows a clear dis-
crimination of EAE stage 3 samples from controls +
EAE stage 1 samples. Hierarchical clustering analysis
also clusters the EAE stage 1 (E1) sample with controls
rather with the more advanced EAE disease samples
(E2 – E5). The possibility that some protein fractions
might be able to discriminate early from advanced EAE
disease is interesting. However, with only one early stage
EAE sample, this clustering may not be significant. In all
cases, the first three principal components account for
most (>80%) of the variation in the data, indicating that
much of the structure in the dataset can be represented
by a relatively low dimensionality analysis.
Table 3 Differentially expressed protein peaks in EAE as compared to control brain tissue
Fraction (Q) Mass (m/z) Acquisition settings p-Value ROC Area Expression change in EAE
1 108995 HMW 0.03 0.00 ↓
2 6540 HMW 0.05 0.13 ↓
2 10274 HMW 0.05 0.07 ↓
2 11691 HMW 0.05 1.00 ↑
2 13365 HMW 0.05 0.07 ↓
2 14349 HMW 0.05 1.00 ↑
2 16836 HMW 0.05 0.00 ↓
2 31521 HMW 0.05 0.07 ↓
2 13331 LMW 0.03 0.00 ↓
2 49085 LMW 0.05 0.06 ↓
3 8044 HMW 0.02 0.00 ↓
3 10416 HMW 0.03 0.07 ↓
3 10862 HMW 0.02 0.00 ↑
3 12448 HMW 0.05 0.96 ↑
3 13954 HMW 0.05 0.03 ↓
3 8251 LMW 0.05 0.00 ↓
3 10855 LMW 0.03 0.00 ↓
3 12493 LMW 0.05 0.95 ↑
3 15498 LMW 0.03 0.00 ↓
4 9841 HMW 0.03 1.00 ↑
4 42924 HMW 0.05 0.93 ↑
4 6583 LMW 0.05 0.07 ↓
4 9115 LMW 0.05 0.07 ↓
5 8528 HMW 0.02 0.00 ↓
5 16910 HMW 0.02 0.00 ↓
5 17307 HMW 0.02 0.00 ↓
5 8392 LMW 0.03 0.00 ↓
5 9801 LMW 0.05 0.93 ↑
5 16878 LMW 0.03 0.00 ↓
5 17280 LMW 0.05 0.00 ↓
6 9717 HMW 0.03 0.00 ↓
6 13854 HMW 0.03 1.00 ↑
6 3006 LMW 0.03 0.00 ↓
6 3266 LMW 0.03 0.00 ↓
6 4272 LMW 0.03 0.00 ↓
6 5455 LMW 0.03 0.00 ↓
6 10637 LMW 0.05 0.07 ↓
6 13809 LMW 0.03 1.00 ↑
6 23228 LMW 0.05 0.93 ↑
Fraction Q: number of the ion exchange fractionation; m/z: mass/charge ratio of the protein peak; LMW: low molecular weight protocol; HMW: high molecular
weight protocol; ↑: protein level was increased in EAE as compared to control; ↓: protein level was decreased in EAE as compared to control.
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Figure 3 Protein expression profile for fraction Q3. (A) Example of SELDI mass spectra of two differentially expressed proteins in anion
exchange fraction Q3 obtained from mitochondrial fractions of brain tissue from EAE mice at disease stage 1 (E1) and disease stage 3 (E2-E5) as
well as brain tissue from controls (C1-C3). The peak at 12448 Da shows increased expression in EAE tissue relative to controls, whereas the peak
at 13954 Da shows a decreased expression in EAE as compared to controls. (B) Scatter plot of scores for principal components 1 and 2 obtained
from a PCA analysis showing the segregation of data into EAE and control samples. (C) Heat map obtained from a hierarchical cluster analysis
showing the clustering of the E1 (disease stage 1) sample with the control samples. The * indicates the two differentially expressed proteins
shown in the SELDI mass spectra given in (A). These two proteins were digested with trypsin and identified by peptide mass fingerprinting and
peptide sequencing with a LTQ-FT mass spectrometer (Table 4).
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SELDI-MS workflows enable the rapid analysis of a large
numbers of protein samples and can generate patterns
of differentially expressed proteins that may distinguish
disease states from controls. However, protein identifica-
tion usually requires separate purification of the proteins
of interest by polyacrylamide gel electrophoresis prior to
trypsin digestion and peptide mass fingerprint analysis,
and confirmation of protein identity by Western blotting
analysis. Unambiguous identification of differentially
expressed proteins can be difficult if protein bands
obtained from 1D polyacrylamide gel electrophoresis
(PAGE) consist of several proteins with similar molecu-
lar weights. However, the subcellular fractionation of thesample into cytosolic, mitochondrial, and nuclear frac-
tions combined with ion exchange fractionation prior to
1D PAGE employed in the current work is actually a
multi-dimensional separation, albeit with low resolution
fractionations (3 subcellular fractions and 6 ion ex-
change fractions) for the first two steps, and one might
expect more success in resolving individual proteins
than with 1D PAGE alone.
Fractions Q2, Q3, Q4, and Q5 from control or EAE
brain tissue were subjected to 1D SDS polyacrylamide
gel electrophoresis together with SeeBlue Plus 2 pre-
stained molecular weight standards. The gels were
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Figure 4 Protein expression profile for fraction Q2. (A) Scatter plot of scores for principal components 1 and 2 obtained from a PCA analysis
showing the segregation of data into EAE (blue) and controls (red). (B) Hierarchical clustering resulted in two major clusters: EAE stage 3 samples
(E2-E5) and control (C1-C3) + EAE stage 1 (E1) samples. The * indicates the four differentially expressed proteins that were subjected to trypsin
digestion and identified by peptide mass fingerprinting and peptide sequencing with a LTQ-FT mass spectrometer.
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of differentially expressed proteins of interest were ex-
cised and the proteins in the gel plugs were treated with
dithiothreitol and iodoacetamide to reduce any disulfide
bonds and alkylate the resulting thiol groups. The pro-
teins were digested with trypsin and identified by pep-
tide mass fingerprinting and peptide sequencing with a
LTQ-FT mass spectrometer at the Center for Proteomics
and Bioinformatics, Case Western Reserve University.
The resulting peak list files were used to interrogate the
indexed IPI mouse database with the Mascot algorithm.
The list of identified proteins is given in Table 4 and is
dominated by components of the electron transport chain
including cytochrome c oxidase subunit 6b1 (COX6b1),
subunit 6C (COX6C), and subunit 4 (COX4i1); NADH
dehydrogenase flavoprotein 3 (Ndufv3), alpha subcomplex
subunit 2 (Ndufa2), Fe-S protein 4 (Ndufs4), and Fe-S pro-
tein 6 (Ndufs6); and ATP synthase subunit e (Atp5k); as
well as myelin basic protein isoforms. Other proteins in-
clude ubiquitin A-52 protein (Uba52), a protein involved
in ion homeostasis; CPN10-like protein Hspe-rs1 (Cpn10-
rs1), which is a member of the GroES chaperonin family;
beta2 microglobulin (B2m); cofilin 1 (Cfl1); V-type proton
ATPase subunit G2 (Atp6v1g2), a vacuolar ATPase
which mediates the acidification of intracellular com-
partments; basic transcription factor 3 (btf3) and the
40S ribosomal protein S13 (Rps13). Because theprotein bands in fraction Q3 each consist of a single
identified protein, the identity of the differentially
expressed proteins as myelin basic protein (MBP)
isoforms is unambiguous. However, we have not con-
firmed which of the other proteins identified in gel
bands represents the differentially expressed protein
peaks observed in SELDI mass spectra. Recent studies
have implicated mitochondrial dysfunction as a pos-
sible mechanism in the development of neuropathol-
ogy in MS (13, 14, 21, 22, 31, and 58) and increased
levels of nitration among proteins of the electron
transport chain result in reduced mitochondrial activ-
ity in EAE [59].
The appearance of a number of components of elec-
tron transport chain complexes (cytochrome c oxidase
subunit 6b1, subunit 6C, and subunit 4; NADH de-
hydrogenase flavoprotein 3, alpha subcomplex subunit 2,
Fe-S protein 4, and Fe-S protein 6; and ATP synthase
subunit e) among the list of potential differentially
expressed proteins is interesting given the identification
of cytochrome c oxidase subunit 4 (32), subunit 5a (30),
and subunit 5b (30, 31) as being differentially expressed
in EAE or MS in previous studies. A recent proteomics
study of spinal cord during the clinical course of EAE
(33) identified 35 differentially expressed proteins out of
800 spots observed by 2D PAGE, including proteins
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Figure 5 Protein expression profile for fraction Q6. (A) Scatter plot of scores for principal components 1 and 2 obtained from a PCA analysis
showing the segregation of data into EAE and control samples. (B) Heat map obtained from a hierarchical cluster analysis showing the clustering
of EAE and control samples into distinct groups. Note also the highly correlated peaks at 3006, 3040, 3266, 4020, and 4272 Da in the lowest node
of the heat map suggesting a strong relationship between the peaks.
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were differentially expressed, and none correspond to
the mitochondrial proteins described here. Farias et al
(33) found decreased expression of vacuolar ATPase
subunit B in EAE relative to controls, while we observe
vacuolar ATPase subunit G2 (Atp6v1g2) in differentially
expressed band Q5. This V-type proton ATPase medi-
ates the acidification of intracellular compartments.
Myelin basic protein
The identity of the differentially expressed proteins in
fraction Q3 as myelin basic protein isoforms was con-
firmed with Western blots (not shown). MBP is not
expected to be associated with mitochondria. Indeed
Ravera et al [60] reported finding no MBP in mitochon-
dria using fresh bovine brain tissue and slightly different
preparation conditions. MBP is a basic protein that in-
teracts with membranes and it is possible that the
mitochondrially-enriched fraction was contaminated
with MBP released from myelin during tissue homogeni-
zation. To test this we added fluorescently labeled MBP
to brain tissue prior to homogenization and measured
the fluorescence intensity of nuclear, mitochondrial andcytoplasmic fractions. Most fluorescence is observed in
the cytoplasmic (70%) and nuclear (22%) fractions, with
less than 2% of the total fluorescence observed in the
mitochondrially enriched fraction. While this is only a
small fraction of the total MBP added, we cannot rule
out contamination of the mitochondrial fraction by free
MBP. Freezing and storage are known to lead to con-
tamination of mitochondria by synaptosomal membrane
fragments [61] and it is possible that freezing and stor-
age of brain tissue blocks prior to homogenization and
subcellular fractionation also leads to contamination of
mitochondria by myelin membrane fragments or myelin
vesicles. To test this we employed Western blots to de-
termine if contamination was also observed in the mito-
chondrial fraction obtained with fresh mouse brain
tissue. The presence of MBP isoforms in mitochondrial
fractions from frozen control and EAE mouse brain tis-
sue was confirmed in a Western blot probed with anti-
bodies to mouse MBP (Figure 6A). The 21.5 kDa MBP
isoform was clearly seen in both frozen control and EAE
mouse samples. In addition, other MBP isoforms or
MBP fragments are observed in the frozen EAE sample.
By contrast, no MBP was detected in mitochondrial

















2 6550 0.05 IPI00138892 Uba52 14719 642 7 46
IPI00225390 COX6b1 10065 84 2 24
10274 0.05 IPI00225390 COX6b1 10065 545 7 67
IPI00120045 Hspe1-rs1 10971 431 3 33
IPI00403381 Ndufv3 11806 430 4 36
11691 0.05 IPI00109966 B2m 13814 499 4 27
IPI00128345 Ndufs6 13012 414 3 31
16836 0.05 IPI00890117 CfI1 18548 663 12 70
IPI00229008 Ndufs4 19772 335 8 48
3 12448 0.05 IPI00115240 MBP1 27151 443 5 15
13954 0.05 IPI00223381 MBP8 14202 584 12 61
4 9841 0.03 IPI00131771 COX6C 8464 1460 9 63
IPI00223593 MBP10 20801 1049 11 50
IPI00111770 Atp5k 8230 473 7 68
IPI00225390 COX6b1 10065 443 6 53
IPI00315302 Ndufa2 10909 428 5 41
5 16910 0.02 IPI00223379 MBP6 17215 2521 14 64
IPI00123817 Atp6v1g2 13643 501 4 39
17307 0.02 IPI00223380 MBP7 17230 1168 12 70
IPI00319231 Rps13 17212 362 7 45
IPI00229008 Ndufs4 19772 354 8 34
IPI00131186 Btf3 17688 329 3 46
Proteins identified in 1D polyacrylamide gel bands which correspond to the molecular weights of differentially expressed proteins in EAE relative to controls
found by SELDI-MS analysis. Only the myelin basic protein isoforms found in fraction Q3 are unambiguously identified.
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lane). The positive control (Figure 6B right lane) was
prepared by adding purified bovine 18.6 kDa MBP iso-
form to the mitochondrial fraction derived from fresh
mouse tissue. This gel was probed with both mouse and
bovine anti-MBP antibodies.
So it appears that the presence of MBP in the mito-
chondrial fraction is an artifact of tissue freezing and
storage. Nevertheless, differential expression of MBP
isoforms and proteolytic fragments appears to be a con-
sistent feature of EAE. Increases in expression of MBP
isoforms also have been observed in mitochondrially-
enriched fractions from MS brain tissue relative to con-
trols, where the differential expression of MBP was an
important factor separating MS samples from controls
in principal component analysis [31]. We have identified
the peak at 13,954 Da, which decreases in EAE relative
to controls, as MBP8 (the 14.2 kDa isoform). There is
also a peak at 12,448 Da, which increases in EAE relative
to controls, and is identified as MBP1, the canonical
MBP, but in fact, the relatively small number of peptides
(five) and sequence coverage (15%), mean this peak
could be any MBP isoform except isoform 3. Its m/zratio is consistent with it being a proteolytic fragment of
MBP. The reduction of the 14.2 kDa MBP isoform and
the increase in the 12.4 kDa MBP fragment in EAE ani-
mals with stage 3 diseases is clearly evident in the SELDI
mass spectra shown in Figure 3A. Proteolysis has long
been thought to play a role in multiple sclerosis, and ele-
vated proteolytic activity has been observed in cerebro-
spinal fluid in MS patients [62]. Several proteases have
been implicated in the degradation of myelin proteins
and the generation of immunogenic peptides in multiple
sclerosis and experimental autoimmune encephalomyeli-
tis (EAE) including calpain, trypsin 4, matrix metal-
loproteinase, myelencephalon-specific protease (MSP),
plasminogen activators and cathepsin D [63-66]. Liu
et al. [65] reported fragmentation of MBP following
traumatic brain injury, and linked this to the protease
calpain with a major cleavage site between Phe-and Lys
of the peptide TQDENPVVHFF-–K. They reported the
degradation of the 21.5 and 18.5kDa MBP-isoforms into
N-terminal fragments of 10 and 8 kDa in the cortex.
They also observed a similar degradation of the 17 and
14 kDa MBP-isoforms. Their identification was based
on three matching tryptic peptides, two of which,
AB
Figure 6 MBP is not observed in mitochondrial fractions from fresh brain tissue. Western blot showing (A) the presence of MBP in a
mitochondrial fraction derived from frozen control (left) and frozen EAE (right) mouse brain and (B) the absence of MBP in mitochondrial
fractions derived from fresh mouse brain tissue (left) together with a positive control prepared by adding purified bovine 18.6 kDa MBP isoform
to the mitochondrial fraction derived from fresh mouse tissue (right).
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our study. Ottens et al. [62] reported significant proteoly-
sis of the 21.5, 14.2, and 18.5 kDa isoforms in a traumatic
brain injury model. Six predicted calpain fragments of
MBP were described including a 12.6 kDa fragment which
may be related to the 12.4 kDa MBP fragment identified
in our fraction Q3. Another EAE study [64] showed that
the 18.5 and 14.2 kDa MBP isoforms were substantially
degraded by calpain to 10 and 11 kDa fragments. Add-
itionally, Matrix metalloproteinases (MMPs) are reported
to play a significant role in the fragmentation of MBP and
demyelination leading to multiple sclerosis and EAE [58].
The mechanisms of myelin breakdown in MS are not
clearly established but degradation of MBP has been
thought to be the initial step in the breakdown of myelin
in demyelinating diseases. This hypothesis is supported by
the degradation and loss of protein from MS plaque
believed to be associated with increased activities of the
proteolytic enzymes in demyelinating conditions such as
MS and EAE.Conclusions
We have demonstrated that SELDI mass spectrometry
can be employed to explore the proteome of a complex
tissue (brain) and have obtained protein profiles of differ-
entially expressed proteins from mitochondrially enriched
protein fractions from experimental autoimmune enceph-
alomyelitis (EAE) and control mouse brain. We have
shown that appropriate homogenization protocols and
protein fractionation using anion exchange beads can be
employed to reduce sample complexity without introdu-
cing significant additional variation into the SELDI mass
spectra beyond that inherent in the SELDI- MS method it-
self. Overall reproducibility is comparable to that reported
by others for analyses performed on a single machine with
a coefficient of variation less than 19%. Although, SELDI-
MS coupled with principal component analysis and hier-
archical cluster analysis provides protein patterns that can
clearly distinguish the disease state from controls, the
identification of individual differentially expressed proteins
requires a separate purification of the proteins of interest
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tion and peptide mass fingerprint analysis. Unambiguous
identification of differentially expressed proteins can be
difficult if protein bands consist of several proteins with
similar molecular weights. Our multi-dimensional use of
subcellular fractionation and ion exchange fractionation
prior to 1D PAGE was insufficient to resolve all proteins,
although the use of a larger number of ion exchange frac-
tions might have resolved more proteins. We have shown
that myelin basic protein isoform 8 (MBP8) (14.2 kDa)
levels are lower in EAE samples with advanced disease
relative to controls, while an MBP fragment (12.4 kDa),
likely due to calpain digestion, is increased in EAE brain
tissue relative to controls. Although differential expression
of MBP and its proteolytic fragments appears to be a con-
sistent feature of EAE, we have shown that MBP is not
found associated with mitochondria obtained from fresh
tissue, and instead its appearance in mitochondrially




Reagents used for the preparation of all buffers were
obtained from Sigma-Aldrich (St. Louis, MO).
Brain tissue samples
EAE was induced in C57Bl/6 mice by subcutaneous in-
jection of MOG35-55 as previously described [67]. EAE
brains from mice at disease stage 1 and 3 and brains
from control littermates were prepared at The University
of Calgary and sent frozen to Kent State University. The
reproducibility study was conducted with pooled tissue
from six control mice brains.
Subcellular fractionation of frozen tissue
Two tissue homogenization methods were tested. In the
first method (M1), 60 μm tissue slices (approximately 250
mg) were cut and a Brinkmann blender was employed to
homogenize the tissue. In the second method (M2), small
blocks (approximately 250 mg) of brain tissue were cut and
homogenized with a TeflonW pestle homogenizer. For
both homogenization methods, frozen brain tissue was
suspended in whole cell homogenization buffer (20 mM
KCl, 3 mM MgCl2, 10 mM 4-(2-hydroxyethyl)-1-piperazine
ethanesulfonic acid (HEPES), pH 7.9 0.5% NP-40, 5% gly-
cerol, with protease inhibitors (P2714, Sigma-Aldrich, St.
Louis, MO)). The cell homogenate was centrifuged at 1500
g for 10 minutes at 4°C. The supernatant was removed and
centrifuged at 10,000 g for 15 minutes at 4°C. The super-
natant was removed and stored at -80°C as the cytosolic
fraction. The pellet containing the mitochondrially en-
riched fraction was washed twice in 20 mM phosphate
buffered saline (PBS) pH 7.4. The mitochondria were thenlysed in mitochondrial lysis buffer (50 mM Tris, 7M urea,
3% CHAPS with protease inhibitors) for 20 minutes at
room temperature. The mitochondrial lysate was
centrifuged at 10,000 g for 10 minutes at 4°C. A modified
Lowry protein assay was used to determine the protein
concentration. All samples were stored at -80°C until
further analysis.
Subcellular fractionation of fresh brain tissue
Brains were removed immediately from killed mice,
weighed (around 300 mg) and immersed in ice cold
mitochondria isolating buffer (MIB) (0.25 M sucrose, 0.5
mM potassium EDTA, 10 mM Tris-HCl pH 7.4). All
glassware and equipment was kept cold (4°C). The brain
tissue was homogenized in 4.0 mL of 12% percoll in
MIB, with a Dounce homogenizer with 30 strokes. The
homogenate (~3.5 mL) was then layered onto a previ-
ously poured 3.5 mL 26% percoll which itself had been
poured over 3.5 mL of 40% percoll. The sample was
centrifuged at 30,000 g for 1 minutes at 4°C. The top
layer containing myelin and other cellular debris was
carefully removed using a Pasteur pipette and discarded.
The second layer containing the mitochondria was care-
fully removed and diluted 1:4 in cold MIB and centrifuge
at 15,000 g for 10 minutes at 4°C. The resulting pellet
was resuspended with 1 mL MIB and centrifuged once
more at 15,000 g for 10 minutes. The pellet was then
vortexed in mitochondria lysis buffer for 1 minute and in-
cubated for 20 minutes at room temperature. The lysate
was centrifuged at 10,000 g for 10 minutes at 4°C. The
supernatant protein concentration was determined and
the samples were stored at -80°C until further analysis.
Ion exchange fractionation
Cytosolic and mitochondrially enriched fractions were
further fractionated using ion exchange chromatography
in a spin column format (UFC30HV00 column, UFC
3000TB centrifuge tube, Millipore, Billerica, MA). Sam-
ples (100 μg each) were equilibrated with 50 μl of buffer
A (9 M Urea, 2% CHAPS in 50 mM Tris HCl pH 9.0)
for 20 minutes at room temperature. Buffer B (buffer A
diluted 1 part to 8 parts with 50 mM Tris HCl, pH 9.0)
was used to dilute samples to 200 μL. The quaternary
ammonium anion exchange beads (Q ceramic HyperD F,
Pall BioSera, New York, NY) were equilibrated with
three changes of 200 μL of buffer B. Samples were
loaded onto the column and mixed on an end-to-end
mixer for 30 minutes at room temperature. Samples
were centrifuged for 1 minute at 1000 g. This eluate was
the flow-through fraction. The column was removed
from the centrifuge tube and placed in the next centri-
fuge tube (Q1, pH 9). 400 μL of pH 9 elution buffer
(50 mM Tris HCl pH 9.0, 0.1 OGP) was loaded onto the
column and placed on the end-to-end mixer for 10
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for fraction Q2 (pH 7.0 elution buffer: 50 mM HEPES
pH 7.0, 0.1% OGP), fraction Q3 (pH 5.0 elution buffer:
100 mM sodium acetate pH 5.0, 0.1% OGP), fraction Q4
(pH 4.0 elution buffer: 100 mM sodium acetate pH 4.0,
0.1% OGP), fraction Q5 (pH 3.0 elution buffer: 50 mM
sodium acetate pH 3.0, 0.1% OGP), and fraction Q6
(organic wash: 33% isopropanol, 17% acetonitrile and
0.1% trifluroacetic acid). All fractions were stored at
-80°C until use. Three fractions (Q1, Q2, and Q4) de-
rived from the cytosolic fraction of pooled control mice
brains were employed for the reproducibility study. The
EAE study employed mitochondrial fractions (Q1- Q6),
from individual EAE and control mice.
ProteinChip array preparation
The samples obtained from ion exchange fractionation
were analyzed using NP20 ProteinChip arrays (Cipher
gen Biosystems, Fremont, CA). Each ProteinChip was
prepared according to the Ciphergen ProteinChip Appli-
cation guide (ProteinChip Applications Guide Volume
2). Briefly, 1 μL of each sample was applied directly to
the ProteinChip array in a randomized manner. After
air-drying for 3 minutes, all spots were treated with 1 μL
applications of matrix (saturated sinapinic acid (SPA) in
0.5% trifluoroacetic acid, 50% acetonitrile) letting the
spots dry between each application.
Data acquisition and processing
Mass spectra were acquired using a model PBSIIc
SELDI-TOF-MS (Ciphergen Biosystems, Fremont, CA).
SELDI mass spectra were acquired with a laser intensity
of 225 and a detector sensitivity of 8 for high molecular
weight proteins (HMW protocol), and a laser intensity
of 199 and a detector sensitivity of 9 for low molecular
weight proteins (LMW protocol). Both high and low
molecular weight spectra were acquired at a digitizer
rate of 250 MHz in positive ion mode with a chamber
vacuum of less than 5×10-7 torr, a source voltage of 20
kV and a detector voltage of 2,700 V. A total of 65 tran-
sients were averaged for each spectrum. Spectral pro-
cessing (smoothing and baseline subtraction) was
performed with ProteinChip 3.1 software. All spectra
were calibrated externally using an All-in-1 peptide
standard [porcine dynorphin, 2147.50 Da; bovine insulin
β-chain, 3495.94 Da; and hirudin BHVK, 7033.61 Da],
and an All-in-1 protein standard [bovine cytochrome c,
12230 Da; bovine carbonic anhydrase, 29024 kDa; and S.
cerevisiae enolase, 46670 Da] (Ciphergen Biosystems,
Fremont, CA). Peak intensities were normalized against
the total ion current (TIC), excluding the mass range
below 1500 Da, which is composed of strong signals
from the SPA matrix. Because automatic peak selection
by the Ciphergen Express software can miss features thatappear as shoulders on large peaks, all spectra were
subjected to manual peak-picking. All peaks that are
present in at least 25% of the spectra and with SNR ≥ 3
were selected.
Data analysis
Univariate (Mann-Whitney test) and multivariate statis-
tical analysis (principal component analysis (PCA)) were
performed using Ciphergen Express software. Analysis
of variance (ANOVA) was employed to calculate the
p-value. SELDI-MS peak intensity differences were con-
sidered significant when p ≤ 0.05. Hierarchical clustering
was performed on all peaks that were present in at least
25% of spectra with SNR > 4.0 and heat maps were gen-
erated [49].
Protein purification
For the EAE study, sample fractions containing differen-
tially expressed proteins of interest were subjected to 1D
electrophoresis on 16% acrylamide Tris-glycine gels.
Briefly, each sample was concentrated in a Thermo
Speed Vac vacuum concentrator, then dissolved in sam-
ple buffer (0.125 M Tris-HCl, 4% SDS, 40% glycerol,
0.1% bromophenol blue, pH 6.8, (Invitrogen)), followed
by heating for 10 minutes at 75°C. 20 uL of sample mix-
ture were loaded onto the appropriate lane in the gel
and electrophoresed at 200Vfor 45 minutes. SeeBlue
Plus2 (Invitrogen) pre-stained molecular weight stan-
dards were employed for calibration. The gel was stained
with Coomassie Brilliant blue R 250 (0.25% Commassie
blue, 40% methanol, 7% acetic acid) and were destained
with destaining solution I (40% methanol, 7% acetic
acid) for one hour, and with destaining solution II
(7% acetic acid, 5% methanol) overnight.
In-gel digestion
The desired protein bands were excised from the gel and
subjected to in-gel trypsin digestion using a procedure
employed at the Center for Proteomics and Bioinformat-
ics, Case Western Reserve University. Gel plugs were
covered with 25 mM ammonium bicarbonate (ABC) at
room temperature for 10 minutes. The supernatant was
replaced with 50% acetonitrile in 25 mM ABC for 10 mi-
nutes. These first two steps were repeated twice. Gel plugs
were then dried in a Thermo Speed Vac vacuum concen-
trator. 10 mM dithiothreitol (DTT) in 25 mM ABC was
added and the reaction allowed to proceed at 56°C for 45
minutes. The supernatant was then replaced with 55 m M
iodoacetamide and the reaction proceeded at room
temperature in the dark for 45 minutes. Trypsin solution
(2 ng/μL trypsin in 25 mM ABC) was added and the
digestion proceeded at 37°C overnight. Formic acid
was used to quench the reaction. The digest solution
containing the extracted peptides was stored at -4°C.
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Proteins were identified by peptide mass fingerprinting
and peptide sequencing using a Dionex Utimate 3000
capillary LC system on line with LTQ-Fourier Transform
(FT) mass spectrometer (Thermo Electron Corp., Bre-
men, Germany) at the Center for Proteomics and Bio-
informatics, Case Western Reserve University. The
tandem mass spectra were annotated and peak list files
were generated. The resulting peak list files were then
used to interrogate sequences present in the indexed IPI
mouse database with the Mascot algorithm (Matrix
Science). A positive identification was accepted when a
minimum of two peptide monoisotopic masses matched
a particular protein with sequence coverage ≥10%, and
low expectation value (p < 0.05).
Western blotting
Protein samples were mixed with SDS-PAGE sample
buffer (Invitrogen) followed by heating at 70°C for 10
minutes. Protein samples were separated by SDS-PAGE
on NuPage 4-12% Bis-Tris mini gels (Invitogen) run at
200 V for 30 minutes, and then transferred to nitrocellu-
lose paper at 45 V for 1 hour. The blot was blocked with
5% non-fat milk dissolved in 0.1% Tween-TBS buffer,
and then incubated with antibody against Myelin Basic
Protein overnight at 4°C. The blot was washed with 0.1%
Tween-TBS buffer and incubated with the secondary
antibody conjugated with horseradish peroxidase (HRP)
for 1 hour. The blot was washed with 0.1% Tween-TBS
buffer and visualized using chemiluminescence reagent
(sc2048, Santa Cruz Biotechnology, Inc., Santa Cruz,
CA). Images were made by exposing X-ray film (Fuji
Super RX) to the blots. The images were analyzed using
Image J software (NIH, Bethesda, MD).
Preparation and use of fluor-labeled MBP
MBP was labeled with HiLyte Fluor 488 (Anaspec,
Fremont, CA) according to the manufacturer’s instruc-
tions. Briefly, 100 μg of MBP was dialyzed overnight
against 50 mM PBS, pH 7.4 at 4°C. Fluor was suspended
in DMSO to generate 10 μL of a 2 mM solution. Protein
labeling was conducted at a 7.5:1 ratio of fluor to protein
at room temperature for 45 minutes. The dye-
conjugated protein was washed with 50 mM PBS, pH
7.4 and separated from unreacted dye by centrifugation
in a spin column.
Sample preparation
Whole brains were harvested from euthanized pregnant
wistar rats and stored at -80°C. Brains were homoge-
nized in parallel with and without 500 μL of fluorescent
MBP added to 1.5 mL of general lysis buffer (20 mM
KCl, 3 mM MgCl2, 10 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES) pH 7.9, 0.5%NP-40, 5% glycerol with protease inhibitors (P2714,
Sigma-Aldrich, St. Louis, MO using a Wheaton
homogenizer with a Teflon® pestle. in thirty strokes. The
homogenate was centrifuged for 10 minutes at 500g at
4°C. The supernatant was removed and centrifuged at
10,000 g for 30 minutes at 4°C. The pellet containing the
mitochondrially enriched fractions was further purified
by washing once in 20 mM phosphate buffered saline
(PBS), pH 7.4. The mitochondrial fractions were stored
at 4°C.
Fluorescent spectroscopy
Emission spectra were acquired on a Cary Eclipse spec-
trofluorimeter. The fluorescence intensity at 523 nm was
employed to compare the levels of fluor-labelled MBP
observed in each sub-cellular fraction.
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